NCT01787799已完成3 期
EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 26
- 主要终点
- In-stent Late Loss
研究概览
简要总结
The purpose of this study is to evaluate 9 month angiographic and intravascular ultrasound (IVUS) data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) in the treatment of subjects with atherosclerotic lesion(s) ≤34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be at least 18 years of age
- •Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
- •For subjects less than 20 years of age enrolled at a Japanese site, the subject and the subject's legal representative must provide written informed consent before any study-specific tests or procedures are performed
- •Subject is eligible for percutaneous coronary intervention (PCI)
- •Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia
- •Subject is an acceptable candidate for coronary artery bypass grafting (CABG)
- •Subject is willing to comply with all protocol-required follow-up evaluation
- •Angiographic Inclusion Criteria (visual estimate)
- •Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.25 mm and ≤4.0 mm
- •Target lesion(s) length must be ≤34 mm (by visual estimate)
- •Target lesion(s) must have visually estimated stenosis ≥50% and <100% with thrombolysis in Myocardial Infarction (TIMI) flow >1 and one of the following (stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress or imaging stress test, or elevated biomarkers prior to the procedure)
- •Coronary anatomy is likely to allow delivery of a study device to the target lesions(s)
- •The first lesion treated must be successfully pre-dilated/pretreated
排除标准
- •Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI)
- •Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina
- •Subject has received an organ transplant or is on a waiting list for an organ transplant
- •Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
- •Planned PCI (including staged procedures) or CABG after the index procedure
- •Subject previously treated at any time with intravascular brachytherapy
- •Subject has a known allergy to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors (clopidogrel, ticlopidine, prasugrel, or ticagrelor), or aspirin)
- •Subject has one of the following (as assessed prior to the index procedure):
- •Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months
- •Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)
- •Planned procedure that may cause non-compliance with the protocol or confound data interpretation
- •Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome
- •Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
- •Subject has a white blood cell (WBC) count < 3,000 cells/mm3
- •Subject has documented or suspected liver disease, including laboratory evidence of hepatitis
- •Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177µmol/L)
- •Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- •Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months
- •Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
- •Subject has severe symptomatic heart failure (i.e., New York Heart Association (NYHA) class IV)
- •Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
- •Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
- •Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure)
- •Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)
- •Angiographic Exclusion Criteria (visual estimate)
- •Planned treatment of more than 3 lesions
- •Planned treatment of lesions in more than 2 major epicardial vessels
- •Planned treatment of a single lesion with more than 1 stent
- •Subject has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate)
- •Target lesion(s) is located in the left main
- •Target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate.
- •Target lesion(s) is located within a saphenous vein graft or an arterial graft
- •Target lesion(s) will be accessed via a saphenous vein graft or arterial graft
- •Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing
- •Target lesion(s) treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)
- •Target lesion(s) is restenotic from a previous stent implantation or study stent would overlap with a previous stent
- •Subject has unprotected left main coronary artery disease (>50% diameter stenosis)
- •Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure
- •Thrombus, or possible thrombus, present in the target vessel (by visual estimate)
结局指标
主要结局
In-stent Late Loss
时间窗: 9 month
In-stent late loss at 9 months post-procedure as measured by quantitative coronary angiography (QCA)
次要结局
未报告次要终点
研究者
研究点 (26)
Loading locations...
相似试验
已完成
3 期
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)AtherosclerosisCoronary Artery DiseaseNCT00824434Boston Scientific Corporation100
招募中
不适用
Intravascular Ultrasound-Guided PCI in Patients With Chronic Kidney DiseaseChronic Kidney DiseasesCoronary Artery DiseaseNCT06567938First Affiliated Hospital Xi'an Jiaotong University1,528
招募中
不适用
Clinical Impact of Intravascular Ultrasound-Based Artificial Intelligence Technologies (INNOVATE-PCI)Coronary Artery DiseaseNCT05807841Asan Medical Center3,000
招募中
不适用
IVUS Analysis for Coronary Obstruction in TAVICoronary Artery OcclusionNCT05164796Universita di Verona100
已完成
不适用
Ultrasound Evaluation of the IVC in Addition to Clinical Assessment to Guide Decongestion in ADHFHeart FailureNCT03140566University of Luebeck388